The Path: Philanthropist Priscilla Chan’s bold bet on rare disease - CNBC

Direct Source Verification: This story is aggregated from CNBC (cnbc.com). Full reporting rights and copyright belong to the primary publisher.
In April, Biohub — the philanthropic organization co-founded by Dr. Priscilla Chan and Mark Zuckerberg — announced a $500 million investment into an AI platform that it hopes will help scientists better understand the way human cells work within the body.

In April, Biohub — the philanthropic organization co-founded by Dr. Priscilla Chan and Mark Zuckerberg — announced a $500 million investment into an AI platform that it hopes will help scientists better understand the way human cells work within the body.

It was one of the biggest bets yet from Chan and Zuckerberg, who believe that in order to make the breakthroughs that will transform what's medically possible we must first invest in basic science. The couple — driven in large part by Dr. Chan's experience working with children suffering from rare diseases while she was in medical school — have also made significant contributions to the rare disease community through their Rare As One Network a major priority.

Priscilla Chan joined Becky Quick in an emotional interview to discuss everything from rare disease research and personalized medicine, to how AI could help advance biomedicine and science.

Priscilla, first of all, thank you so much for taking the time to sit down with us.

I know that you are a doctor and a co-CEO, and on your Instagram profile, it says a long litany of other things, including a former teacher, I think you also said you are a super nerd or a science nerd, and you're a mom. Of all of these things that you are, what do you think of yourself first and foremost? And I think I know the answer to that.

Sounds like that's how you identify, right?

I mean, that's me too. Totally. So, what's number two?

Number two, I think it's got to be science nerd, but in part because I, it touches so many things and aspects of life. It encapsulates like I'm just so optimistic of where we can be going, and also I love knowing how things work.

I think so. I've just always wanted to know why.  I always knew I wanted to help kids somehow, take care of kids, educate kids, help them feel well, be well, and I always wanted to know how the human body worked, and I think the earliest like core memory where it went from I like this to I need to do this was when my grandfather passed.

My grandfather died when I was in middle school when I was like around 12 years old, and we came from sort of a family with relatively low medical literacy. And he went from being totally well, dropping me off at school that morning, to my cousins picking me up from school and rushing me to the hospital to say goodbye by the end of the school day, and for years that's all we knew. That's all I knew and understood, and there were very vague explanations, but no one could tell me why. And when I got a chance in high school to design an independent study, I wanted to know why.

Yes. And so I, I knew he had cancer. My school was very supportive. I bought a cancer textbook, and I just started reading it. And that was they gave me course credit, but really, I was trying to answer why for myself. And if you asked me, actually, like this is not my natural habitat. I love it here now, but this is not my natural habitat. So in college and in med school, if you asked anyone what the niche that I loved was the healing niche. To stand alongside families, to sit with them, and to understand, and to support, and that's still incredibly important to me. And sort of like needing to tinker and to know exactly why. If we look back, you know, that's why I ordered that cancer textbook in high school, but it didn't become like a need to do, a passion until much later.

What happened? What did you find out about your grandfather when you did this study project?

So I think what happened was that he had a GI bleed because of his cancer, but it wasn't actually his cancer that killed him. It was a GI bleed, and it was just not talked about. 

I – It's so complicated. There are some cultures where you don't really talk about health issues, and you just brush it under the rug, and you assume that you know the standard course of treatment is going to be fine. And I, and it probably was fine, and this probably was just the course, natural course for him, but it felt so unsettled for me to not know why.

Yeah, you were really close to your grandfather too. Your mom and dad were immigrants, and they were working two jobs a day to make sure that you guys had a roof over your head and you had food. But it was your grandfather who was, and your grandmother, who were home taking care of you.

I grew up in a multi generational household. In our three bed, one bath, I had my two grandparents, my two sisters, and my two parents, and we just that was how we grew up, and we all took care of each other.

Did you feel resolved when you finished your project and kind of came to your conclusions about what had happened to him?

I think what I learned is not like I think I've pieced together what happened to him, but I think oftentimes we just look at the surface level of, like you know, someone has this symptom, you treat the symptom with this drug or treatment course or whatever it is, and what it left with me is like, no, I need to know exactly what happened, and I need to know exactly the course of events, and I need to know like the pathophysiology, and if we don't know why we can't do better and we can't help the next patient with a better course of treatment, and so I think what it left with me was a very deep needing to know why and being unsatisfied if we don't understand exactly why something is happening.

So then you went to Harvard and you went to medical school and you wound up at UCSF for your residency. Why UCSF?

For two reasons. I came out here. Mark, you know, dropped out of college very famously. I finished many more degrees than him, and he was out in Palo Alto, and I came out to Palo Alto, and I took a year off between college and med school to teach. I was like, I'm going to go to the best med school available to me, and hopefully, it's close enough where we can continue this relationship, and thank goodness UCSF saw something in me, because my life would look really different if we didn't, I didn't get into UCSF.

It's a very special place. Most people don't know anything about it because it doesn't have an undergraduate program. It's a medical campus in the UC system, and it does two things. It does cutting-edge research. It's what we call a tertiary or quaternary care center. It treats patients with very rare and exotic diseases as well as common, and it has a dedication to serving the public and public good, and so it allowed me to both grow, continue to grow my scientific brain, as well as be able to serve those who are traditionally not well served by the medical system. 

I mean, I know why I got to rare, but I think this is why you got to rare disease, right? What happened?

So I trained as a pediatrician at UCSF, and the kids, really babies and young children, that end up at UCSF oftentimes don't have a diagnosis, or they have a series of letters that describes a mutation. As a trainee, as a medical student, and as a resident, you're like, I don't know what this is, and when I look it up in the sort of like general textbook, it's not there. So then you're like, am I the only one who doesn't know? And then you quickly discover that nobody knows. And then a parent gives you a PDF in the patient room. I mean, this has happened to me so many times, and I can still imagine it happening. They're like, "Here it is. This is everything we know about my kid." And you read it, and you're like, "Wait, but this doesn't tell me what IV fluids to order, what kind of diet, what medications work. Like, this is barely anything, and this is everything we know?" It's both shocking how thin the knowledge is on these mutations or these diseases, and how much trial and error there has to be. You, I'm sure you've been in that seat. Where it's like, actually, could you tell me what will help your kid? I'm happy to do it, but like, what has worked in your experience? And that's what we're going on with really rare diseases, and that's when I got rehooked into basic science, because I thought by going to medical school I was going to know it. I was going to know the answer. If I just studied what they told me, I'd be able to help the kids that came in through the door, and that's not true, because we don't know enough yet about how the human body works. We do have to go back to the pipettes and the lab and PCR and all those things, because we have to push the frontier of knowledge. You know this better than most people. It's just sometimes you just need hope, either for yourself or for the next kid, to keep going.

Yeah, I mean, hope goes a very long way, and I love what you are doing by focusing on the basic building blocks and tools of science to get us back to that. I've got a million questions. Almost 11 years ago was when you all started the Chan Zuckerberg Initiative. You were still finishing up the finishing touches when, what was going on in your life?

Oh my gosh, my firstborn Max. We were just writing down our hopes and dreams, and I was like, and it was just it was such a first time parent thing to do. It's like, what are our hopes for this? Little did you know, survival was the first hope after having your first child, but we really took a step back and said, "What do we want to contribute? What do we want to do? What do we think we could actually do to make the world a better place for all children, including our own?" And what we knew… we were just getting started. We knew very little, but we knew that Mark had experience as an engineer. He had experience building things, breaking things down into components, understanding them, and then building up from there. I had the experience of being on the frontlines with kids, either in the classroom or in the hospital, and seeing like where the gaps were, and so that's where we went from. Like, what do we as people bring additionally to the table?

How do we deploy them to make a contribution? Because one of the first things we learned is that this work is so much bigger than one person, one organization, one team. It's really, you have to work together with many others in the field of science in this case, and figure out what you bring uniquely to lift everyone else up.

What were the early experiences that kind of taught you that getting to that point? Were there some failures along the way, where you thought this is not enough, we have to go bigger, broader?

Well, first you just look at the numbers. You know, we have an incredible scientific engine in our country, and the amount that we contribute, if you just look at the financials, is like 1%. So it's not something any one group can do. And then what you start… 

You guys personally at CZI contribute 1%?

Wow. Getting into this, I mean, you're about to be first time parents. You have an incredible amount of wealth, and you all made a pretty big decision. I think you signed onto The Giving Pledge. You said that you were going to give 99% of of your wealth from Meta, in your lifetime that you'd be giving that away. So at that point, I think it was something like $45 billion we were talking about. As of this week, I think it's closer to $255 billion. Those are big, big, big numbers. How do you figure that out? Like, what do we do with this? How do we do it? Because that's just so exponentially… the numbers.

I think you can… There's both the urgency, which we have felt, but we realized in our urgency that we needed to figure out the niche where we could uniquely contribute. In science, we just really hit the flywheel. Like we, one of our first investments was in single cell sequencing. All of your cells have the same genome, but they're obviously very different. Your hair cell is different than your heart cell. They share the same genes, exact same genes. What is it that makes them different? How does, how is it that they work so differently? And so you need to start looking at the RNA level. What parts of the genome are they reading and describing for their function? And we just… we funded scientists to say like, how do you do this? Let's write it down, and then we just hit the positive flywheel of like, oh yeah, we can look at the lung, we could look at the kidney. During COVID, we discovered a whole new type of lung cell that is uniquely affected by COVID, that no one knew before. We realized that we were looking at different cell types that no one had ever characterized, and that's how early we are in truly understanding how the human body works. The criticism was: this is just stamp collecting. Like there's so much knowledge. You're just generating numbers and letters. And what is the meaning of this?

Yeah, but from our perspective, Mark was like, how can you debug something? How can you find the error when you don't understand the underlying system that the human is built on, and for him, doing that single cell sequencing laid that foundation. For me, I knew that there were kids out there that had like 40 base pairs that were different, and what did those 40 base pairs do that made them so sick, and grow and develop so much more differently than other kids? That's it, 40 letters in their genome. It has to mean something. And so we were willing to go down that path, gathering this information, and then we hit an amazing flywheel where people started building together. We funded a, maybe a third now of what is now the Human Cell Atlas, looking at the RNA transcriptome. But because we put it out there as open science, open source, come join us, people started using it, and then also realizing, 'Oh, this is useful. I can contribute to this.' So now it's one of the largest RNA repositories of the different cells in your body, and the vast majority of it isn't funded by us. It's a community that has come together, and that's super powerful. Imagine our delight when large language models came on board.

Because the power of large language models is making sense out of a whole lot of information, too much information for any one human brain to actually understand. But we had too much information for any one human being to understand that we thought could explain how your body works, and so we were like, we've got to put these together. 

When did that happen? When did that kind of connection where you thought, large language models, everything we're doing right now with CZI and Biohub, whoa!

This is going back years at this point.

It's years ago. I remember being like, "What is an LLM?" Right, because it's not my background, and I'm looking it up, and I'm like, oh my gosh, I I actually, this will make you laugh. I really need to know why things work, so I started taking linear algebra. It's all based on linear algebra, and I was like, okay, I took, it was not a very sophisticated course but I took enough to understand. Okay, so we're making sense of patterns. I knew it was going to be big because we had the ability to generate this data and work with the community to build this data, and this tool is coming online that was still early, but was doing amazing things. A little bit more than a year ago, we started talking to the ESM team that was known for building protein models.

Evolutionary scale models, that's what ESM is for people who don't know it. And it's kind of phenomenal when you put, when you pulled that in, scientists were able to compute structures for 1.1 billion proteins in a week. 

What does that match up to, like say historically? What could be done?

This is kind of a fun story, and I don't think people realize how biology works. You do.

For biological breakthroughs, you have to be clever and kind of lucky, right? And some of the most amazing breakthroughs have come from people like being really creative and seeing the connections between things. You know, CRISPR came out of work on I want to say bacteria and yogurt. I don't know if you know this, but GLP 1's comes from a guy at the VA who was studying Gila monster venom.

Yeah, and it was Pfizer who originally had it and put it back on the market afterwards. 

It went from Gila monster venom to diabetes to, I mean, who knows the… it could… the ceiling is high. Someone got lucky and studied something random and it was like oh my gosh I see the connection. It is not systematic. It is, you can't say I have this problem. How do I get to an answer? And I think the thing that's so powerful about the rare disease community is that you guys have seen both how frustrating it is to wait and be like, maybe someone will see a connection that I don't see, or maybe a scientist will get interested in my disease, and you kind of either sit and wait and try to get lucky, or you say this doesn't work. We need to systematically look at what my kid or these groups of kids have, understand the genetic basis of it, and then keep marching until we understand why and what we could do differently. What I believe the future of medicine is is we can look at the genetics, say, ah, this set of genes and inputs changes the way that this group of cells work. But if you design a protein that looks like this, then you change the function of the cells, and you can help them work correctly. That has to be the future of medicine, and the incredible contribution of the rare disease community is that they saw it first. You've seen it first. You've pushed for science that works that way, and a lot of rare disease groups, as you know, are gathering data, patient registries, samples, data sets, to allow scientists to build upon this.

You think that the rare disease model is really kind of the gateway to personalized medicine for everybody. 

Yes, it's for sure… the future of medicine has to work this way, and … because right now, let me give you a wild like example, like very common disease, depression. Like when you're diagnosed with depression, a doctor will start a common drug, and then you'll wait like six to eight weeks. Did it help? It didn't? Oh, I wonder why. Let's try the next drug. But we actually don't know why one drug worked and one drug didn't. And we actually don't know the genetic basis or the sort of changes that happen that lead someone to… 

Or why one drug works for one person and another for somebody else.

We don't, but that's suffering and poor treatment that a patient has to go through in searching for the right treatment for a common disease. But what if we actually understood sort of the genetic predispositions of someone and say you're most likely to respond to this treatment. That's great. That's better. Or for someone who has something very bespoke and unique to them, we can say you have this set of genes that lead this protein to be misfolded. And this is where a model like ESM that does protein folding can already do, which is we can design proteins straight from the model, a computational model, to give us instructions, and we can make those proteins, and they fold the way we would expect, and they bind to what we want it to bind. We saw that when the models came out a couple months ago, and that is like designing treatments for the future, but it's now. People are doing it.

Let's talk about how quickly that can happen, and maybe just go back to the origins of CZI again. You're actually in the delivery room when you're working out the final details. Just explain that because that's really hard for me to imagine.

Well, I had an epidural, so let's start there.

I need an epidural and a bottle of wine to handle that.

But we were working through, like, what do we bring to the table, and what changes do we want to see, and it was not… It was about organizing our thoughts and making a commitment. Like we are committed to this work, and sort of the path that we're going to take changes. Like here we are talking about large language models. 10 years ago, that was not a thing that we could have written down, but we're committed to doing the work and learning and growing as we sort of learn more about what's possible. We have learned a lot, and we've also got a ton of new tools, and I think that that's the thing that's so exciting, and we originally set out. Well, let's walk through the true timeline. We said we wanted to cure, prevent, or manage all disease. 

They were like, "That's impossible." And well, we thought, okay, why? Well, if you look at the pace of, sort of, of scientific discovery, it's accelerated, but not that fast. And we're like, okay. And they were like, well, maybe one. I was like, no, no, no. The point is not one disease. One disease would lead you down the path of saying, "Let's find those clever connections." It was very important that it was all disease because it was about truly understanding how the human body works, so that we could systematically work through different ways that it can go wrong. And so that 'all' part set us on a very specific strategy of deep understanding of how the body works. And then we talk to scientists who are like, okay, scientists could barely keep a straight face while talking about this. We're like, okay, but humor us, why? And they would say, like, we don't have enough interdisciplinary collaboration. We don't have shared tools. We don't have the data sets. Publishing is not moving as fast as it can be. We're like, okay, you've just outlined what we should tackle first. So that's how we got started, and then we kept going, we kept going, and we were like, "Okay, we're making progress on these things." And now, if we said at the end of the century, if I said that to you now, you'd say, "Why so long?"

Right, to cure all disease by the end of the century.

Yeah, because now with the tools that we're seeing and the speed at which new knowledge is being learned, and the accuracy in which we can speed up… the accuracy of our science that's sped up by computation with models, and then in the lab, it's fast.

So, what do you consider success? What would success look like in 5, 10, 20 years? What do you think is possible? 

I bet sometime by the end of next year, we're seeing discoveries and impact in animals and humans that have been empowered by models that we're building and using today. It used to take decades to get a clinical trial put together. Rare disease groups have broken that mold. We have rare disease groups that we've supported that have gone from not knowing what their mutation meant to designing a gene therapy that's in humans now within 10 years, the program has existed for 10 years. That's lightning speed, but that's without sort of the foundational models and data sets and research that we have coming online today, and so that can be even faster, and the exciting thing is that there's momentum across the scientific ecosystem of people coming together to build this.

Let's talk about the origins of Biohub because you started the Chan Zuckerberg Initiative almost 11 years ago. A year later was Biohub. Why a different organization? Why a different grouping?

For us, the Biohub really represents a focus on basic science, and now frontier science and frontier AI coming together, and it was important that that was a clear position that we took and Biohub took to say this is what we bring to the table.

And let's talk about what you're next hoping to do. How did you get to Rare As One? How did that come about? What's the kind of goal of the program? What are you doing right now?

So Rare As One started eight years ago, and it wasn't really on my radar because we were working on like we're working on petri dishes and cells, right? Single cells. And I was… we were just going to build our way up. And Tanya, who runs the program, came to us and said, "Well, like actually, the people moving science fast right now are rare disease groups." And at first, I was like, I don't know. It's not a traditional area for philanthropy to fund, and I was really… it was a new area for me, and I was not familiar with it. But she started showing me the work that the rare disease groups had done around natural history, registries, samples, actually pulling together patients for science to move quickly. And I was like, "Yeah, I believe you" because I've seen those patients in the hospital, and those patients and families could move mountains. And I was like, "Okay, that is true. These people are powerful, and they have the desire, the motivation to do this." And I was like, okay, let's try it. Let's just try it. We did the first cycle, and we were super like cautious about it, and sort of thoughtful of how this would come together. And we were just completely blown away by the patient groups that applied and how they were already doing work with so little, and were helping each other already. And it was that cohort effect of like, how do we do this? How do we do this together? How can we teach each other? That was so powerful, and like the results are undeniable. 10 years, 8 years in, groups are you know driving research that didn't exist before, driving clinical trials that didn't exist, FDA approved studies for treatments for genetic therapies. Like that's lightning speed, and so it's been incredible. And now, I always believed this, but now I see the credible pathway: all of medicine is going to go this way, and so I can confidently say today that I probably couldn't even say three years ago. They're not just trailblazing for their own disease or for rare disease groups. They are trailblazers for the future of medicine, which is so exciting, and the legacy that these families are going to leave is going to be huge.

Where do you think you go from here?

I think you start looking at how you can actually start applying their lessons to how the human body works, and like that's the goal. The goal is, you know, for any one group, yes, your mutation is your top priority, and it should be. But they're actually showing us the future of science, and so how can we take those lessons, take that power that the patients and families have had, and help apply it to move medicine forward for everyone?

I'm so hopeful sitting here talking to you about this, and it's you know you go through your ups and downs where you think you're making advances, think maybe you're not, but when you sit down and explain the bigger picture, I mean that is mind blowing. That is what is wow. That's the future.

It is, and we're gonna get to live it. I think it's all going to move faster, and I think the thing that's interesting is that the rare disease groups are not just pioneers for themselves. I think we're going to look back and realize that the rare disease groups were pioneers for all of biomedicine, and we're going to see the way that research goes from research to clinical trials to treatments much faster because we've seen groups pioneer it happen differently with the rare disease groups and with the foundational models that are getting built today.

From your lips. I mean, that is the promise all of us are hoping for. You're a scientist and a tinkerer and somebody who looks at how things work, which has you really grounded in reality. But I think you have to be a dreamer to think about the things that you're doing too. How do you see yourself? How do you and Mark kind of play together in that relationship on being grounded in science and in engineering, but then also dreaming big dreams for this stuff?

I think for us, is the realization is we don't have to know the whole path there. We can set a goal. We want to cure, prevent, and manage all disease. And then we just need to do the next thing. And if we try the next thing and we learn from it, it's the speed of learning that's going to get us to the goal. It's not that we know exactly the right path and all the steps to get there. It's a willingness to do something that we don't know whether or not it's going to work, and learn from it and keep going and get smarter. And I think that's what we've done over the past 10 years. And what's really fun is that, you know, Mark from his perspective is just like, of course it takes a long time to build things. I've built things. It takes a long time, and you need to build the foundation, and you need to sort of build the learning engine. And once you have that going, you're going to make progress. And for me, I'm always like a hawk looking at like, is this going to matter for patients? Like, are we doing this because we're just truly curious people, which is fine. But for me, I'm truly curious because I want human lives to be better, and so we're always bringing those perspectives and sort of continuing to hone the learning engine that is Biohub, and that's allowed us to build pretty great things with great people.

That sounds like you carry some pretty heavy responsibilities. Do you ever get tired?

You know, I will say that yes, of course, but there… I'm not sure there's been a more exciting time in science and in medicine, and so I, my mind is blown, and I'm delighted by the work that we get to be able to do.

What kind of reaction do you get when you tell people today that you want to cure all disease?

People are like, yeah, of course, that's going to happen, and they ask me how, instead of saying that's not possible.

I think back to your time at UCSF, and I just wonder. I know you said there are a lot of families that the patients, the families stuck with you. Is there one in particular who really jolted you? Maybe one of your first patients that you met along the way. 

Oh boy. There are two that come to mind when you ask that question. We had a kid who had cystic, we had lots of kids with cystic fibrosis, actually, but he was like the picture of health. I was like why, you look so good? He was a college age kid, and he was doing college age things, and I was like, why is this kid doing so well when I see so many kids with other kids with cystic fibrosis that are really struggling? What is the difference? What happened here? And so sometimes the positive outliers make you say, maybe there's something there. Like maybe there's something that we're not seeing that helped this kid thrive. And then there was another case. I think as a doctor, you always remember the first patients that you sort of take care of until the end of their life, and I took care of this kid for eight weeks every day in the hospital, and it was a relapse. It was a, it was a cancer, pediatric cancer that had relapsed, and she had done so well, and she had gone home, and she had lived her life, and she was a teen too, and she came back, and the medicines didn't work anymore. And then you have to ask yourself, like, why? Why didn't the medicines work? And honestly, I think you just never forget the patients that you say goodbye to. 

But you honor their memory with what you're doing today. 

Yeah, you know she wrote me a card. I still have it. These are the things you save.

Yeah. As a parent of a child with a rare disease, I'm grateful. Thank you for what you all are doing.

We're all doing our best. You're doing incredible work. I don't think people realize how much you do in all your different hats.

It's not that, it's… you're finding solutions. I can't do what you guys do, and I'm blown away. So thank you.

CNBC Cures is underwritten by Alexion, AstraZeneca Rare Disease and BridgeBio.

Original Source
https://www.cnbc.com/2026/11/20/the-path-philanthropist-priscilla-chans-bold-bet-on-rare-disease.html
Visit CNBC ↗
SHARE STORY:
𝕏 f in

Related Coverage in Health